Poor outcomes in elderly kidney transplant recipients receiving alemtuzumab induction

American Journal of Nephrology

Volumn 34, Issue 6, 2011, Pages 534-541

  Hurst, Frank P ^a   Altieri, Maria ^b   Nee, Robert ^a   Agodoa, Lawrence Y ^c   Abbott, Kevin C ^a   Jindal, Rahul M ^d,e,f  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Alemtuzumab; Complications; Elderly recipients; Induction agents; Kidney transplantation; Kidney transplants; outcomes

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; DACLIZUMAB; THYMOCYTE ANTIBODY;

AGE DISTRIBUTION; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; GERIATRIC SURGERY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SURGICAL MORTALITY; SURGICAL RISK; TREATMENT OUTCOME;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COHORT STUDIES; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; RISK; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 81355122850     PISSN: 02508095     EISSN: 14219670     Source Type: Journal    
DOI: 10.1159/000334092     Document Type: Article

References (30)

1. Fishman JA: Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614. (Pubitemid 350294226)
2. Hawksworth JS, Leeser D, Jindal RM, Falta E, Tadaki D, Elster EA: New directions for induction immunosuppression strategy in solid organ transplantation. Am J Surg 2009; 197: 515-524.
3. Shapiro R, Young JB, Milford EL, Trotter JF, Bustami RT, Leichtman AB: Immunosuppression: Evolution in practice and trends, 1993-2003. Am J Transplant 2005; 5: 874-886. (Pubitemid 40461261)
4. Meier-Kriesche HU, Schold JD, Kaplan B: Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289-1295. (Pubitemid 39013575)
5. Kirk AD: Induction immunosuppression. Transplantation 2006; 82: 593-602. (Pubitemid 44395228)
6. Szczech LA, Berlin JA, Feldman HI: The effect of antilymphocyte induction therapy on renal allograft survival. A meta-analysis of individual patient-level data. Anti-Lymphocyte Antibody Induction Therapy Study Group. Ann Intern Med 1998; 128: 817-826. (Pubitemid 28267714)
7. Webster AC, Ruster LP, McGee R, et al: Interleukin 2 receptor antagonists for kidney transplant recipients. Cochrane Database Syst Rev 2010; 1:CD003897.
8. Markmann JF, Fishman JA: Alemtuzumab in kidney-transplant recipients. N Engl J Med 2011; 364: 1968-1969.
9. Annual Report of the US Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1999-2008. Rockville, US Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, 2009.
10. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B: Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int 2001; 59: 1539-1543. (Pubitemid 32281245)
11. Laftavi MR, Patel S, Soliman MR, et al: Lowdose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy. Transplant Proc 2011; 43: 466-468.
12. Huang E, Cho YW, Hayashi R, Bunnapradist S: Alemtuzumab induction in deceased donor kidney transplantation. Transplantation 2007; 84: 821-828. (Pubitemid 351338941)
13. Farney AC, Doares W, Rogers J, et al: A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation. Transplantation 2009; 88: 810-819.
14. Gill J, Sampaio M, Gill JS, et al: Induction immunosuppressive therapy in the elderly kidney transplant recipient in the United States. Clin J Am Soc Nephrol 2011; 6: 1168-1178.
15. Patel SJ, Knight RJ, Suki WN, et al: Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age. Clin Transplant 2011; 25:E250-E256.
16. Hanaway MJ, Woodle ES, Mulgaonkar S, et al: Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909-1919.
17. Jacobs SA, Foon KA: Monoclonal antibody therapy of leukaemias and lymphomas. Expert Opin Biol Ther 2005; 5: 1225-1243. (Pubitemid 41244833)
18. Calne R, Moffatt SD, Friend PJ, et al: Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients. Transplantation 1999; 68: 1613-1616.
19. Kirk AD, Hale DA, Mannon RB, et al: Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120-129. (Pubitemid 36877125)
20. Ciancio G, Burke GW, Gaynor JJ, et al: A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457-465. (Pubitemid 41209412)
21. Ciancio G, Gaynor JJ, Roth D, et al: Randomized trial of thymoglobulin versus alemtuzumab (with lower dose maintenance immunosuppression) versus daclizumab in living donor renal transplantation. Transplant Proc 2010; 42: 3503-3506.
22. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP: Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction - long-term results. Am J Transplant 2005; 5: 2539-2548.
23. Farney A, Sundberg A, Moore P, et al: A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation. Clin Transplant 2008; 22: 41-49. (Pubitemid 351150001)
24. Ciancio G, Burke GW 3rd: Alemtuzumab (Campath-1H) in kidney transplantation. Am J Transplant 2008; 8: 15-20.
25. Ortiz J, Palma-Vargas J, Wright F, et al: Campath induction for kidney transplantation: Report of 297 cases. Transplantation 2008; 85: 1550-1556.
26. Ciancio G, Burke GW, Gaynor JJ, et al: Campath- 1H induction therapy in African American and Hispanic first renal transplant recipients: 3-year actuarial follow-up. Transplantation 2008; 85: 507-516.
27. Morris PJ, Russell NK: Alemtuzumab (Campath-1H): A systematic review in organ transplantation. Transplantation 2006; 81: 1361-1367. (Pubitemid 43847142)
28. Noel C, Abramowicz D, Durand D, et al: Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients. J Am Soc Nephrol 2009; 20: 1385-1392.
29. Sollinger H, Kaplan B, Pescovitz MD, et al: Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. Transplantation 2001; 72: 1915-9191.
30. Ulrich F, Niedzwiecki S, Pascher A, et al: Long-term outcome of ATG vs. Basiliximab induction. Eur J Clin Invest 2011; 41: 971-978.